In a key decision, the Centers for Medicare and Medicaid Services (CMS) said today that Medicare will not pay for the controversial Alzheimer’s drug Adulhelm until it sees positive results from a government-approved trial.
Subscribe to:
Post Comments (Atom)
< + > The Growing Gap Between Healthcare Risk and Healthcare Governance
The following is a guest article by Sam Peters, Chief Product Officer at IO Healthcare organizations are moving quickly to adopt artificial...
No comments:
Post a Comment